TPA-induced p21 expression augments G2/M arrest through a p53-independent mechanism in human breast cancer cells

Oncology Reports

Volumn 27, Issue 2, 2012, Pages 517-522

  Han, Jeonghun ^a   Kim, Sangmin ^a   Yang, Jung Hyun ^b   Nam, Seok Jin ^a   Lee, Jeong Eon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Konkuk University Hospital   (South Korea)

Author keywords

12 O tetradecanoylphorbol 13 acetate; Cell cycle; ERK; p21; p53

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P21; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; UO 126;

ARTICLE; BREAST CANCER; CELL CYCLE REGULATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WILD TYPE;

BREAST NEOPLASMS; BUTADIENES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INHIBITORS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MAP KINASE SIGNALING SYSTEM; NITRILES; PHOSPHORYLATION; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862912277     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1511     Document Type: Article

References (33)

1. Wen-Sheng W: Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2. Cancer Lett 239: 27-35, 2006.
2. Shimao Y, Nabeshima K, Inoue T and Koono M: TPA-enhanced motility and invasion in a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1: selective role of PKC-alpha and its inhibition by a combination of PDBu-induced PKC downregulation and antisense oligonucleotides treatment. Clin Exp Metastasis 17: 351-360, 1999. (Pubitemid 29477581)
3. Schlingemann J, Hess J, Wrobel G, et al: Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. Int J Cancer 104: 699-708, 2003. (Pubitemid 36418506)
4. Kim S, Lee HS, Lee SK, et al: 12-O-Tetradecanoyl phorbol-13-acetate (TPA)-induced growth arrest is increased by silibinin by the down-regulation of cyclin B1 and cdc2 and the up-regulation of p21 expression in MDA-MB-231 human breast cancer cells. Phytomedicine 17: 1127-1132, 2010.
5. Salabat MR, Ding XZ, Flesche JB, et al: On the mechanisms of 12-O-tetradecanoylphorbol-13-acetate-induced growth arrest in pancreatic cancer cells. Pancreas 33: 148-155, 2006. (Pubitemid 44174562)
6. el-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993. (Pubitemid 23346378)
7. Weiss RH: p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4: 425-429, 2003.
8. Li Y, Dowbenko D and Lasky LA: AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 277: 11352-11361, 2002. (Pubitemid 34952901)
9. Lawlor MA and Rotwein P: Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21. Mol Cell Biol 20: 8983-8995, 2000. (Pubitemid 32245928)
10. Asada M, Yamada T, Ichijo H, et al: Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18: 1223-1234, 1999. (Pubitemid 29110307)
11. Fan Y, Borowsky AD and Weiss RH: An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther 2: 773-782, 2003.
12. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999. (Pubitemid 29297917)
13. Sugrue MM, Shin DY, Lee SW and Aaronson SA: Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci USA 94: 9648-9653, 1997. (Pubitemid 27408116)
14. Sur S, Pagliarini R, Bunz F, et al: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106: 3964-3969, 2009.
15. Woods DB and Vousden KH: Regulation of p53 function. Exp Cell Res 264: 56-66, 2001. (Pubitemid 32989081)
16. Petitjean A, Mathe E, Kato S, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629, 2007. (Pubitemid 46744292)
17. Dittmer D, Pati S, Zambetti G, et al: Gain of function mutations in p53. Nat Genet 4: 42-46, 1993. (Pubitemid 23165910)
18. Hsiao M, Low J, Dorn E, et al: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 145: 702-714, 1994. (Pubitemid 24285977)
19. Sheikh MS, Rochefort H and Garcia M: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11: 1899-1905, 1995.
20. Kikkawa U, Takai Y, Tanaka Y, Miyake R and Nishizuka Y: Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem 258: 11442-11445, 1983. (Pubitemid 13019291)
21. Detjen KM, Brembeck FH, Welzel M, et al: Activation of protein kinase C alpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. J Cell Sci 113 (Pt 17): 3025-3035, 2000.
22. Agadir A, Chen G, Bost F, Li Y, Mercola D and Zhang X: Differential effect of retinoic acid on growth regulation by phorbol ester in human cancer cell lines. J Biol Chem 274: 29779-29785, 1999.
23. Koeffler HP: Human myelogenous leukemia: enhanced clonal proliferation in the presence of phorbol diesters. Blood 57: 256-260, 1981.
24. Tahara E, Kadara H, Lacroix L, Lotan D and Lotan R: Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction. Cancer Biol Ther 8: 801-807, 2009.
25. Schwaller J, Peters UR, Pabst T, et al: Up-regulation of p21WAF1 expression in myeloid cells is activated by the protein kinase C pathway. Br J Cancer 76: 1554-1557, 1997. (Pubitemid 27520580)
26. Ullmannova V, Stockbauer P, Hradcova M, Soucek J and Haskovec C: Relationship between cyclin D1 and p21(Waf1/Cip1) during differentiation of human myeloid leukemia cell lines. Leuk Res 27: 1115-1123, 2003. (Pubitemid 36960031)
27. Das D, Pintucci G and Stern A: MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells. FEBS Lett 472: 50-52, 2000. (Pubitemid 30224584)
28. Blagosklonny MV, Prabhu NS and El-Deiry WS: Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res 57: 320-325, 1997. (Pubitemid 27036613)
29. Coppock DL, Buffolino P, Kopman C and Nathanson L: Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity. Exp Cell Res 221: 92-102, 1995.
30. Sugibayashi R, Shimizu T, Suzuki T, Yamamoto N, Hamada H and Takeda K: Upregulation of p21(WAF1/CIP1) leads to morphologic changes and esterase activity in TPA-mediated differentiation of human prostate cancer cell line TSU-Pr1. Oncogene 20: 1220-1228, 2001. (Pubitemid 32226248)
31. Balmanno K and Cook SJ: Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 18: 3085-3097, 1999. (Pubitemid 29261229)
32. Cozzi SJ, Parsons PG, Ogbourne SM, Pedley J and Boyle GM: Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res 66: 10083-10091, 2006.
33. Chen C, Chang YC, Liu CL, Chang KJ and Guo IC: Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat 98: 121-132, 2006.